MedTrace Logo

Premature Ventricular Contractions (PVCs) and Blood Pressure Control

NCT01833455 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-02-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if reduction in premature ventricular contraction (PVC) burden results in a decrease in blood pressure, sympathetic outflow, plasma catecholamines and an improvement in baroreflex gain. Flecainide will be used for PVC suppression in a randomized, double-blinded, crossover fashion.

Conditions

  • Ventricular Premature Complexes
  • Blood Pressure

Interventions

DRUG

PVC Suppression using Flecainide

Flecainide will be administered to result in a reduction in PVC burden.

DRUG

No PVC Suppression using Placebo

Placebo (sugar pills) will be given to result in no alteration in PVC burden.

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Mohamed H Hamdan, MD, MBA · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2016-06-30
Completion
2016-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01833455 on ClinicalTrials.gov